Medicus Pharma Ltd $MDCX Stock: Interchange Capital Partners LLC Grows Holdings

Interchange Capital Partners LLC raised its holdings in Medicus Pharma Ltd (NASDAQ:MDCX) by 33.9% during the third quarter, Holdings Channel reports. The institutional investor owned 2,124,910 shares of the company’s stock after buying an additional 538,039 shares during the quarter. Interchange Capital Partners LLC’s holdings in Medicus Pharma were worth $343,000 as of its most recent SEC filing.

Separately, Private Advisor Group LLC grew its holdings in shares of Medicus Pharma by 36.8% during the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock valued at $110,000 after buying an additional 64,560 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Alliance Global Partners reissued a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research report on Friday, October 2nd. Finally, Wall Street Zen downgraded Medicus Pharma to a “strong sell” rating in a research note on Saturday, October 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $450.00.

Medicus Pharma Trading Down 12.6%

Shares of Medicus Pharma stock opened at $1.88 on Friday. The stock has a fifty day simple moving average of $7.27 and a 200 day simple moving average of $23.43. Medicus Pharma Ltd has a 12-month low of $1.82 and a 12-month high of $127.50. The company has a market capitalization of $2.37 million, a P/E ratio of -0.02 and a beta of 0.30.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($10.50) EPS for the quarter, missing analysts’ consensus estimates of ($6.38) by ($4.12). On average, analysts predict that Medicus Pharma Ltd will post -36.25 EPS for the current year.

Medicus Pharma Company Profile

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.